CR10261A - Formulaciones novedosas - Google Patents

Formulaciones novedosas

Info

Publication number
CR10261A
CR10261A CR10261A CR10261A CR10261A CR 10261 A CR10261 A CR 10261A CR 10261 A CR10261 A CR 10261A CR 10261 A CR10261 A CR 10261A CR 10261 A CR10261 A CR 10261A
Authority
CR
Costa Rica
Prior art keywords
formulations
new formulations
fpf
variability
therapy
Prior art date
Application number
CR10261A
Other languages
English (en)
Inventor
John Capecchi
James Stefely
Trevor Riley
Original Assignee
3M Innovative Properties Co
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38523271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10261(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 3M Innovative Properties Co, Glaxo Group Ltd filed Critical 3M Innovative Properties Co
Publication of CR10261A publication Critical patent/CR10261A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/23—Solid materials, e.g. granules, powders, blocks or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas novedosas en aerosol, procedimientos para su preparación, su uso en terapia, inhaladores de dosis medida que contiene dichas formulaciones y el uso de polimeros biocompatibles para reducir la variabilidad de la uniformidad de contenido y/o para proporcionar fracción de particula fina (FPF) mejorada en dichas formulaciones.
CR10261A 2006-03-22 2008-08-28 Formulaciones novedosas CR10261A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78463406P 2006-03-22 2006-03-22

Publications (1)

Publication Number Publication Date
CR10261A true CR10261A (es) 2008-11-26

Family

ID=38523271

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10261A CR10261A (es) 2006-03-22 2008-08-28 Formulaciones novedosas

Country Status (18)

Country Link
EP (1) EP2012797A2 (es)
JP (1) JP2009530419A (es)
KR (1) KR20080110854A (es)
CN (1) CN101415428A (es)
AR (1) AR060039A1 (es)
AU (1) AU2007226899A1 (es)
BR (1) BRPI0708798A2 (es)
CA (1) CA2646236A1 (es)
CR (1) CR10261A (es)
EA (1) EA200801854A1 (es)
IL (1) IL193723A0 (es)
MA (1) MA30328B1 (es)
MX (1) MX2008011967A (es)
NO (1) NO20083760L (es)
PE (1) PE20080124A1 (es)
TW (1) TW200803870A (es)
WO (1) WO2007109698A2 (es)
ZA (1) ZA200807682B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5809985B2 (ja) 2009-02-26 2015-11-11 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569450A (en) * 1993-03-17 1996-10-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
EP2067784A3 (en) * 2000-08-05 2012-08-22 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative

Also Published As

Publication number Publication date
ZA200807682B (en) 2009-11-25
IL193723A0 (en) 2009-08-03
WO2007109698A3 (en) 2008-12-18
MA30328B1 (fr) 2009-04-01
MX2008011967A (es) 2009-01-14
BRPI0708798A2 (pt) 2011-06-14
NO20083760L (no) 2008-12-17
AR060039A1 (es) 2008-05-21
TW200803870A (en) 2008-01-16
KR20080110854A (ko) 2008-12-19
EA200801854A1 (ru) 2009-04-28
CN101415428A (zh) 2009-04-22
WO2007109698A2 (en) 2007-09-27
PE20080124A1 (es) 2008-04-21
JP2009530419A (ja) 2009-08-27
EP2012797A2 (en) 2009-01-14
AU2007226899A1 (en) 2007-09-27
CA2646236A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
CY1125382T1 (el) Συνθεση για εισπνοη που περιεχει ακλιδινιο για τη θεραπευτικη αντιμετωπιση του ασθματος
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
IL216467B (en) Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate or formoterol and their use in treatment of pulmonary diseases
EA201401354A1 (ru) Новая дозированная форма и препарат, содержащий абедитерол
ECSP088403A (es) Formulacion farmaceutica de absorción oral y su método de administracion
BR112012007182A2 (pt) uso de um material arrastado em dessecante, válvula de dosagem de inalador pressurizado de dose medida, sistema de recipiente fechado de inalador pressurizado de dose medida, e, método para estabilizar a massa de partícula fina (mpf) de uma formulação de droga de inalação
NZ588913A (en) Liver cancer drug
MX2007008379A (es) Metodos y composiciones para minimizar la acumulacion de insulina inhlable en los pulmones.
MX336225B (es) Composiciones que comprenden sulfato de salbutamol.
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
FI20135152A7 (fi) Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa
CR10112A (es) Enmascaramiento del sabor de polvos.
BR112014008602A2 (pt) composição farmacêutica, recipiente vedado, inalador de dosagem medida, métodos para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica
EA200801213A1 (ru) Игла для прокалывания капсул с порошком для ингаляции
BR112015026053A8 (pt) composição farmacêutica, recipiente vedado, inalador dosimetrado, uso de um componente propelente, e, método para fabricação de uma composição farmacêutica
WO2012040228A3 (en) Aerosol composition for administering drugs
CY1115266T1 (el) Φαρμακευτικες συνθεσεις αερολυματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
EA200801854A1 (ru) Новые композиции
MX2010007569A (es) Productos farmaceuticos para inhalacion, sistemas y usos.
UA109530C2 (uk) Композиції, способи та системи для доставки респіраторним шляхом двох чи більше активних агентів

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)